Publications - IR Sant Pau

Search

01/02/2022 Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

Pinto Á, Reig O, Iglesias C, Gallardo E, García-Del Muro X, Alonso T, Anguera G, Suárez C, Muñoz-Langa J, Villalobos-León L, Rodríguez-Sánchez Á, Lainez N, Martínez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzmán JC, Méndez-Vidal MJ, Rubio G, García I, Capdevila L, Lambea J, Vázquez S, Fernández O, Hernando-Polo S, Cerezo S, Santander C, García-Marrero R, Zambrana F, González-Del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, García A, Sotelo M, Arévalo MG, García-Donas J, Hernández C, Bolós MV, Llinares J, Climent MA. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study. Clinical Genitourinary Cancer. 2022; 20(1)DOI:10.1016/j.clgc.2021.09.006. PMID:34789409. IF:3.200(Q2/4D).

01/02/2022 Oral Health-Related Quality of Life Changes in Patients with Dentofacial Deformities Class II and III after Orthognathic Surgery: A Systematic Review and Meta-Analysis

Duarte, V, Zaror, C, Villanueva, J, Andreo, M, Dallaserra, M, Salazar, J, Pont, A, Ferrer, M. Oral Health-Related Quality of Life Changes in Patients with Dentofacial Deformities Class II and III after Orthognathic Surgery: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health. 2022; 19(4)DOI:10.3390/ijerph19041940. PMID:35206128. IF:4.614(Q1/3D).

01/02/2022 Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

Cortellini, A, Ricciuti, B, Vaz, VR, Soldato, D, Alessi, JV, Dall'Olio, FG, Banna, GL, Muthuramalingam, S, Chan, S, Majem, M, Piedra, A, Lamberti, G, Andrini, E, Addeo, A, Friedlaender, A, Facchinetti, F, Gorria, T, Mezquita, L, Hoton, D, Valerie, L, Nana, FA, Artingstall, J, Comins, C, Di Maio, M, Caglio, A, Cave, J, McKenzie, H, Newsom-Davis, T, Evans, JS, Tiseo, M, D'Alessio, A, Fulgenzi, CAM, Besse, B, Awad, MM, Pinato, DJ. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. Journal for ImmunoTherapy of Cancer. 2022; 10(2)DOI:10.1136/jitc-2021-004374. PMID:35173031. IF:10.900(Q1/2D).

01/01/2022 A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Kuemmel, S, Campone, M, Loirat, D, Lopez, RL, Beck, JT, De Laurentiis, M, Im, SA, Kim, SB, Kwong, A, Steger, GG, Adelantado, EZ, Duhoux, FP, Greil, R, Kuter, I, Lu, YS, Tibau, A, Ozguroglu, M, Scholz, CW, Singer, CF, Vega, E, Wimberger, P, Zamagni, C, Couillebault, XM, Fan, LQ, Guerreiro, N, Mataraza, J, Sand-Dejmek, J, Chan, A. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH. 2022; 28(1)DOI:10.1158/1078-0432.CCR-20-3955. PMID:34615719. IF:11.500(Q1/1D).

01/12/2021 Effector Mechanisms of CD8+HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy

Osuna-Gomez, R, Arqueros, C, Galano, C, Mulet, M, Zamora, C, Barnadas, A, Vidal, S. Effector Mechanisms of CD8+HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy. Cancers. 2021; 13(24)DOI:10.3390/cancers13246167. PMID:34944786. IF:6.575(Q1/3D).

01/12/2021 PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study

Rubio-Viqueira, B, Tarruella, MM, Lazaro, M, Estevez, SV, Cordoba-Ortega, JF, Maiques, IM, Gonzalez, JG, Cordellat, AB, Valdivia-Bautista, J, Arenas, CG, Torres, JMS. PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study. Lung Cancer Management. 2021; 10(4)DOI:10.2217/lmt-2021-0008. PMID:34899993. IF:(Q/D).

01/12/2021 Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group

Caamano, AG, Vicente, AMGM, Maroto, P, Antolin, AR, Sanz, J, Gonzalez, MAV, Climent, MA. Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group. Current Oncology. 2021; 28(6)DOI:10.3390/curroncol28060428. PMID:34940067. IF:3.109(Q3/8D).

01/12/2021 Immunotherapy-induced isolated ACTH deficiency in cancer therapy

Iglesias, P, Peiro, I, Biagetti, B, Paja-Fano, M, Cobo, DA, Gomez, CG, Mateu-Salat, M, Genua, I, Majem, M, Riudavets, M, Gavira, J, Lamas, C, Pombo, AF, Guerrero-Perez, F, Villabona, C, Agricola, JMC, Webb, SM, Diez, JJ. Immunotherapy-induced isolated ACTH deficiency in cancer therapy. ENDOCRINE-RELATED CANCER. 2021; 28(12)DOI:10.1530/ERC-21-0228. PMID:34609950. IF:5.905(Q1/3D).

01/11/2021 Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers

Kim, SJ, Lubinski, J, Huzarski, T, Moller, P, Armel, S, Karlan, BY, Senter, L, Eisen, A, Foulkes, WD, Singer, CF, Tung, N, Bordeleau, L, Neuhausen, SL, Olopade, OI, Eng, C, Weitzel, JN, Fruscio, R, Narod, SA, Kotsopoulos, J, Cajal, T.R., Trister, Rachel. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2021; 30(11)DOI:10.1158/1055-9965.EPI-21-0296. PMID:34426412. IF:4.090(Q2/4D).

01/07/2022 SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022)

Capdevila, J, Gomez, MA, Guillot, M, Paez, D, Pericay, C, Safont, MJ, Tarazona, N, Vera, R, Vidal, J, Sastre, J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022). Clinical & Translational Oncology. 2022; 24(7)DOI:10.1007/s12094-022-02855-2. PMID:35596046. IF:3.400(Q3/6D).

01/07/2022 SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021) (vol 24, pg 712, 2022)

Majem, M, de las Penas, R, Virizuela, JA, Cabezon-Gutierrez, L, Cruz, P, Lopez-Castro, R, Mendez, M, Mondejar, R, Munoz, MD, Escobar, Y. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021) (vol 24, pg 712, 2022). Clinical & Translational Oncology. 2022; 24(7)DOI:10.1007/s12094-022-02846-3. PMID:35567734. IF:3.400(Q3/6D).

01/04/2022 SEOM clinical guideline emesis (2021)

Majem, M, de las Penas, R, Virizuela, JA, Cabezon-Gutierrez, L, Cruz, P, Lopez-Castro, R, Mendez, M, Mondejar, R, Munoz, MD, Escobar, Y. SEOM clinical guideline emesis (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02802-1. PMID:35347571. IF:3.400(Q3/6D).

01/11/2021 Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ?

Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., de Álava E., Dei Tos A.P., Garcia del Muro X., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Gaspar N., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Gronchi A., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krákorová D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., López Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schöffski P., Sleijfer S., Strauss D., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Ladenstein R., Casali P.G., Stacchiotti S., EURACAN, GENTURIS and ERN PaedCan. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ?. ANNALS OF ONCOLOGY. 2021; 32(12)DOI:10.1016/j.annonc.2021.08.1995. PMID:34500044. IF:51.769(Q1/1D).

01/07/2023 Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

Valcarcel, S, Gallego, J, Jimenez-Fonseca, P, Diez, M, de Castro, EM, Hernandez, R, Arrazubi, V, Custodio, A, Cano, JM, Montes, AF, Macias, I, Visa, L, Calvo, A, Tocino, RV, Lago, NM, Limon, ML, Granja, M, Gil, M, Pimentel, P, Macia-Rivas, L, Perez, CH, Mangas, M, Carnicero, AM, Cerda, P, Gonzalez, LG, Navalon, FG, Rambla, MDM, Richard, MM, Carmona-Bayonas, A. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; 149(7)DOI:10.1007/s00432-022-04294-6. PMID:36042046. IF:2.700(Q3/6D).

01/01/2023 A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study

Isla D., Felip E., Garrido P., Insa A., Majem M., Remon J., Trigo J.M., de Castro J.. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. Clinical & Translational Oncology. 2023; 25(1)DOI:10.1007/s12094-022-02941-5. PMID:36168085. IF:2.800(Q2/5D).

01/11/2022 Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Aparicio, J, Manrique, ACV, Capdevila, J, Boza, FM, Galvan, P, Richart, P, Oliveres, H, Paez, D, Hernando, J, Serrano, S, Vera, R, Hernandez-Yague, X, Gallego, RA, Riesco-Martinez, MC, de Albeniz, XG, Maurel, J. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01). Clinical & Translational Oncology. 2022; 24(11)DOI:10.1007/s12094-022-02868-x. PMID:35761123. IF:3.400(Q3/6D).

01/11/2022 A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

Climent, MA, Font, A, Duran, I, Puente, J, Mendez-Vidal, MJ, Saez, MI, Lobera, CS, Arija, JAA, Gonzalez-Del-Alba, A, Sanchez-Hernandez, A, Fita, MJJ, Esteban, E, Alonso-Gordoa, T, Gonzalez, BM, Maroto, P, Lazaro-Quintela, M, Cassinello-Espinosa, J, Perez-Valderrama, B, Garcias, C, Castellano, D. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. EUROPEAN JOURNAL OF CANCER. 2022; 175DOI:10.1016/j.ejca.2022.08.002. PMID:36099670. IF:8.400(Q1/2D).

10/10/2022 COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer

Herbst, RS, Majem, M, Barlesi, F, Carcereny, E, Chu, Q, Monnet, I, Sanchez-Hernandez, A, Dakhil, S, Camidge, DR, Winzer, L, Soo-Hoo, Y, Cooper, ZA, Kumar, R, Bothos, J, Aggarwal, C, Martinez-Marti, A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(29)DOI:10.1200/JCO.22.00227. PMID:35452273. IF:45.300(Q1/1D).

01/10/2022 Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)

Gonzalez-Barrallo, I, Rubio, VEC, Medina, J, Espana, S, Mujika, K, Majem, M, Aguado, C, Suarez, MAC, Palacio, I, Osterloh, L, Martinez-Fernandez, A, Garcia-Castano, A. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL). MELANOMA RESEARCH. 2022; 32(5)DOI:10.1097/CMR.0000000000000837. PMID:35762583. IF:2.200(Q3/7D).

01/10/2022 Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events

Alserawan, L, Anguera, G, Atenza, CZ, Lopez, JS, Martinez-Martinez, L, Melia, MR, Sullivan, I, Joaquin, AB, Tarruella, MM, Vidal, S. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(20)DOI:10.3390/ijms232012641. PMID:36293498. IF:5.600(Q1/3D).

12/09/2022 Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain

Majem, M, Alvarez, R, Ortega, AL, de Alda, LR, Gordo, R, Garcia, JF, Ivanova-Markova, Y, Gonzalez-Dominguez, A, San Cristobal, RS, Rojo, F. Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain. Global & Regional Health Technology Assessment. 2022; 9DOI:10.33393/grhta.2022.2449. PMID:36628311. IF:(Q/D).

01/09/2022 Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia

Hwang, TJ, Kesselheim, AS, Tibau, A, Lee, CC, Vokinger, KN. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncology Practice. 2022; 18(9)DOI:10.1200/OP.21.00909. PMID:35731996. IF:4.000(Q2/4D).

01/09/2022 Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Casarrubios, M, Provencio, M, Nadal, E, Insa, A, Garcia-Campelo, MD, Lazaro-Quintela, M, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, Carpeno, JD, Cobo, M, Vivanco, GL, Del Barco, E, Bernabe, R, Vinolas, N, Aranda, IB, Massuti, B, Sierra-Rodero, B, Martinez-Toledo, C, Fernandez-Miranda, I, Serna-Blanco, R, Romero, A, Calvo, V, Cruz-Bermudez, A. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Journal for ImmunoTherapy of Cancer. 2022; 10(9)DOI:10.1136/jitc-2022-005320. PMID:36171009. IF:10.900(Q1/2D).

24/08/2022 In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma

Hernandez, A, Munoz-Marmol, AM, Esteve-Codina, A, Alameda, F, Carrato, C, Pineda, E, Arpi-Llucia, O, Martinez-Garcia, M, Mallo, M, Gut, M, del Barco, S, Gallego, O, Dabad, M, Mesia, C, Bellosillo, B, Domenech, M, Vidal, N, Aldecoa, I, de la Iglesia, N, Balana, C. In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-18608-8. PMID:36002559. IF:4.600(Q2/4D).

01/07/2022 Cabozantinib for the treatment of solid tumors: a systematic review

Maroto, P, Porta, C, Capdevila, J, Apolo, AB, Viteri, S, Rodriguez-Antona, C, Martin, L, Castellano, D. Cabozantinib for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221107112. PMID:35847482. IF:4.900(Q2/4D).

01/07/2022 Cabozantinib combination therapy for the treatment of solid tumors: a systematic review

Castellano, D, Apolo, AB, Porta, C, Capdevila, J, Viteri, S, Rodriguez-Antona, C, Martin, L, Maroto, P. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221108691. PMID:35923927. IF:4.900(Q2/4D).

15/06/2022 ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges

Chow, LQM, Barlesi, F, Bertino, EM, van den Bent, MJ, Wakelee, HA, Wen, PY, Chiu, CH, Orlov, S, Chiari, R, Majem, M, McKeage, M, Yu, CJ, Garrido, P, Hurtado, FK, Arratia, PC, Song, YB, Branle, F, Shi, M, Kim, DW. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. CLINICAL CANCER RESEARCH. 2022; 28(12)DOI:10.1158/1078-0432.CCR-21-1838. PMID:35091443. IF:11.500(Q1/1D).

01/06/2022 Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

Majem, M, Goldman, JW, John, T, Grohe, C, Laktionov, K, Kim, SW, Kato, T, Vu, HV, Lu, S, Li, SQ, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Atagi, S, Zeng, LM, Kulkarni, D, Medic, N, Tsuboi, M, Herbst, RS, Wu, YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. CLINICAL CANCER RESEARCH. 2022; 28(11)DOI:10.1158/1078-0432.CCR-21-3530. PMID:35012927. IF:11.500(Q1/1D).

01/06/2022 SELNET clinical practice guidelines for bone sarcoma

Blay, JY, Palmerini, E, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sanchez, CHS, Montoya, AC, Casavilca-Zambrano, S, Castro-Oliden, V, Chacon, M, Clara-Altamirano, MA, Collini, P, Genoroso, RC, Costa, FD, Cuellar, M, Tos, APD, Malagon, HRD, Donati, DM, Dufresne, A, Eriksson, M, Farias-Loza, M, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gerderblom, H, Gouin, F, Gomez-Mateo, MC, Gronchi, A, Haro, J, Hindi, N, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, Lopes, A, David, BBL, Lopez-Pousa, A, Lutter, G, Maki, RG, Martinez-Said, H, Martinez-Tlahuel, JL, Mello, CA, Perez, JMM, Moura, DS, Nakagawa, SA, Nascimento, AG, Ortiz-Cruz, EJ, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Santos, TG, Scotlandi, K, Silva, MLG, Soule, T, Stacchiotti, S, Valverde, CM, Waisberg, F, Estrada, EZ, Martin-Broto, J. SELNET clinical practice guidelines for bone sarcoma. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174DOI:10.1016/j.critrevonc.2022.103685. PMID:35460913. IF:6.200(Q1/3D).

01/05/2022 Influence of Malignant Pleural Fluid from Lung Adenocarcinoma Patients on Neutrophil Response

Mulet, M, Osuna-Gomez, R, Zamora, C, Porcel, JM, Nieto, JC, Perea, L, Pajares, V, Munoz-Fernandez, AM, Calvo, N, Sorolla, MA, Vidal, S. Influence of Malignant Pleural Fluid from Lung Adenocarcinoma Patients on Neutrophil Response. Cancers. 2022; 14(10)DOI:10.3390/cancers14102529. PMID:35626131. IF:5.200(Q2/3D).

01/01/2022 Clinical benefit of cancer drugs approved in Switzerland 2010-2019

Adam, R, Tibau, A, Valiente, CM, Seruga, B, Ocana, A, Amir, E, Templeton, AJ. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PLoS One. 2022; 17(6)DOI:10.1371/journal.pone.0268545. PMID:35687539. IF:3.700(Q2/4D).

01/11/2023 Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer

Nadal E., Oré-Arce M., Remon J., Bernabé-Caro R., Covela-Rúa M., de Castro-Carpeño J., Massutí-Sureda B., Guillot-Morales M., Majem M., Maestu-Maiques I., Morilla-Ruíz I., Gironés R.. Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer. Clinical & Translational Oncology. 2023; 25(11)DOI:10.1007/s12094-023-03286-3. PMID:37566345. IF:2.800(Q2/5D).

03/09/2023 Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma.

Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, López-Vacas R, Soriano V, Garicano F, Lecumberri MJ, Rodríguez de la Borbolla M, Majem M, Pérez-Ruiz E, González-Cao M, Oramas J, Magdaleno A, Fra J, Martín-Carnicero A, Corral M, Puértolas T, Ramos-Ruiz R, Dittmann A, Nanni P, Fresno Vara JÁ, Espinosa E. Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma.. Cancers. 2023; 15(17)DOI:10.3390/cancers15174407. PMID:37686682. IF:4.500(Q1/3D).

01/09/2023 SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)

Garcia-Saenz, JA, Blancas, I, Echavarria, I, Hinojo, C, Margeli, M, Moreno, F, Pernas, S, Cajal, TRY, Ribelles, N, Bellet, M. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03203-8. PMID:37148499. IF:2.800(Q2/5D).

01/09/2023 SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)

Sanchez-Heras, A, Cajal, TRY, Pineda, M, Aguirre, E, Grana, B, Chirivella, I, Balmana, J, Brunet, J. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03202-9. PMID:37133731. IF:2.800(Q2/5D).

01/09/2023 SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

Garcia-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, O, Cruz-Castellanos, P, Moran, T, Reguart, N, Zugazagoitia, J, Domine, M. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03216-3. PMID:37418123. IF:2.800(Q2/5D).

01/09/2023 SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023)

Garcia-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, OJ, Cruz-Castellanos, P, Moran, T, Reguart, N, Zugazagoitia, J, Domine, M. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03290-7. PMID:37556098. IF:2.800(Q2/5D).

01/09/2023 SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

Segura, PP, Quintela, NV, Garcia, MM, Berron, SD, Sarrio, RG, Gomez, JG, Castano, AG, Martin, LMN, Rubio, OG, Losada, EP. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03245-y. PMID:37540408. IF:2.800(Q2/5D).

01/09/2023 SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

Serrano C., Álvarez R., Carrasco J.A., Marquina G., Martínez-García J., Martínez-Marín V., Sala M.Á., Sebio A., Sevilla I., Martín-Broto J.. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03177-7. PMID:37129716. IF:2.800(Q2/5D).

31/08/2023 Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain

Garcia-Carbonero R., González Astorga B., Vidal Tocino R., Contreras Toledo D., Pericay C., Fernández Montes A., Falcó E., González Cordero M., Reina Zoilo J.J., Alonso V., Rodríguez Salas N., Gil-Raga M., Santos C., Páez D., Anton-Pascual B., Aguilar F., Morales P.. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Clinical & Translational Oncology. 2023; DOI:10.1007/s12094-023-03309-z. PMID:37651021. IF:2.800(Q2/5D).

03/08/2023 A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

Macaulay V.M., Lord S., Hussain S., Maroto J.P., Jones R.H., Climent M.Á., Cook N., Lin, CC, Wang, SS, Bianchini D., Bailey M., Schlieker L., Bogenrieder T., de Bono J.. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. BRITISH JOURNAL OF CANCER. 2023; 129(6)DOI:10.1038/s41416-023-02380-1. PMID:37537253. IF:6.400(Q1/2D).

01/08/2023 PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

Isla, D, Sanchez, A, Casal, J, Cobo, M, Majem, M, Reguart, N, Zugazagoitia, J, Bernabe, R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023; 12(15)DOI:10.3390/jcm12155063. PMID:37568465. IF:3.000(Q1/2D).

01/08/2023 Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

Grunwald, V, Powles, T, Kopyltsov, E, Kozlov, V, Alonso-Gordoa, T, Eto, M, Hutson, T, Motzer, R, Winquist, E, Maroto, P, Keam, B, Procopio, G, Wong, SR, Melichar, B, Rolland, F, Oya, M, Rodriguez-Lopez, K, Saito, K, McKenzie, J, Porta, C. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. European Urology Oncology. 2023; 6(4)DOI:10.1016/j.euo.2023.01.010. PMID:36720658. IF:8.300(Q1/1D).

01/08/2023 The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria

Mayayo-Vallverdu, C, de Heredia, ML, Prat, E, Gonzalez, L, Guarch, ME, Vilches, C, Munoz, L, Asensi, MA, Serra, C, Llebaria, A, Casado, M, Artuch, R, Garrabou, G, Garcia-Roves, PM, Pallardo, FV, Nunes, V. The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria. Redox Biology. 2023; 64DOI:10.1016/j.redox.2023.102801. PMID:37418888. IF:10.700(Q1/1D).

01/07/2023 Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment

Canto, E, Anguera, G, Jimenez, N, Mellado, B, Ramirez, O, Mariscal, A, Maroto, P, Vidal, S. Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment. Diagnostics. 2023; 13(13)DOI:10.3390/diagnostics13132222. PMID:37443615. IF:3.000(Q1/2D).

06/06/2023 Detecting ALK, ROS1, and RET fusions and the MET?ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques

Giménez-Capitán A., Sánchez-Herrero E., de Lope, LR, Aguilar-Hernández A., Sullivan I., Calvo V., Moya-Horno I., Viteri S., Cabrera C., Aguado C., Armiger N., Valarezo J., Mayo-de-las-Casas C., Reguart N., Rosell R., Provencio M., Romero A., Molina-Vila M.A.. Detecting ALK, ROS1, and RET fusions and the MET?ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. Molecular Oncology. 2023; 17(9)DOI:10.1002/1878-0261.13468. PMID:37243883. IF:5.000(Q1/3D).

05/06/2023 SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) (May, 10.1007/s12094-023-03203-8, 2023)

Garcia-Saenz, JA, Blancas, I, Echavarria, I, Hinojo, C, Margeli, M, Moreno, F, Pernas, S, Cajal, T, Ribelles, N, Bellet, M. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) (May, 10.1007/s12094-023-03203-8, 2023). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03229-y. PMID:37273149. IF:2.800(Q2/5D).

04/06/2023 Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Tsuboi M., Herbst R.S., John T., Kato T., Majem M., Grohé C., Wang J., Goldman J.W., Lu S., Su, WC, De Marinis F., Shepherd F.A., Lee K.H., Le N.T., Dechaphunkul A., Kowalski D., Poole L., Bolanos A., Rukazenkov Y., Wu, YL. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(2)DOI:10.1056/NEJMoa2304594. PMID:37272535. IF:96.300(Q1/1D).

01/06/2023 Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib

de Velasco G., Alonso-Gordoa T., Rodríguez-Vida A., Anguera G., Campayo M., Pinto Á., Ortega E.M., Gallardo E., Núñez N.F., García-Carbonero I., Reig O., Méndez-Vidal M.J., Fernández-Calvo O., Cassinello N.V., Torregrosa D., López-Martín A., Rosero A., Valiente P.G., de España C.G., Climent M.A., Santasusana M.D., Sánchez Á.R., González I.C., Afonso R., García del Muro X., Casinello J., Fernández-Parra E.M., García Sánchez L., Afonso J., Polo S.H., Asensio Ú.. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. Clinical Genitourinary Cancer. 2023; 21(3)DOI:10.1016/j.clgc.2022.11.021. PMID:36610891. IF:2.300(Q2/5D).

01/06/2023 Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition

Roldan-Romero, JM, Valdivia, C, Santos, M, Lanillos, J, Maroto, P, Anguera, G, Calsina, B, Martinez-Montes, A, Monteagudo, M, Mellid, S, Leandro-Garcia, LJ, Montero-Conde, C, Cascon, A, Roncador, G, Coloma, J, Robledo, M, Rodriguez-Antona, C. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. INTERNATIONAL JOURNAL OF CANCER. 2023; 153(6)DOI:10.1002/ijc.34575. PMID:37260183. IF:5.700(Q1/2D).

01/05/2023 p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Kobel, M, Kang, EY, Weir, A, Rambau, PF, Lee, CH, Nelson, GS, Ghatage, P, Meagher, NS, Riggan, MJ, Alsop, J, Anglesio, MS, Beckmann, MW, Bisinotto, C, Boisen, M, Boros, J, Brand, AH, Brooks-Wilson, A, Carney, ME, Coulson, P, Courtney-Brooks, M, Cushing-Haugen, KL, Cybulski, C, Deen, S, El-Bahrawy, MA, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Gayther, SA, Barquin-Garcia, A, Gentry-Maharaj, A, Gilks, CB, Gronwald, H, Grube, M, Harnett, PR, Harris, HR, Hartkopf, AD, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Huang, YJ, Jakubowska, A, Jimenez-Linan, M, Jones, ME, Kennedy, CJ, Kluz, T, Koziak, JM, Lesnock, J, Lester, J, Lubinski, J, Longacre, TA, Lycke, M, Mateoiu, C, McCauley, BM, McGuire, V, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Paz-Ares, L, Cajal, TRY, Rothstein, JH, Ruebner, M, Schoemaker, MJ, Shah, MT, Sharma, R, Sherman, ME, Shvetsov, YB, Singh, N, Steed, H, Storr, SJ, Talhouk, A, Traficante, N, Wang, C, Whittemore, AS, Widschwendter, M, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, dos Reis, FJC, Campbell, I, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Fortner, RT, Garcia, MJ, Goodman, MT, Goode, EL, Gronwald, J, Huntsman, DG, Karlan, BY, Kelemen, LE, Kommoss, S, Le, ND, Martin, SG, Menon, U, Modugno, F, Pharoah, PDP, Schildkraut, JM, Sieh, W, Staebler, A, Sundfeldt, K, Swerdlow, AJ, Ramus, SJ, Brenton, JD. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology Clinical Research. 2023; 9(3)DOI:10.1002/cjp2.311. PMID:36948887. IF:3.400(Q1/3D).

01/05/2023 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Remon, J, Besse, B, Aix, SP, Callejo, A, Al-Rabi, K, Bernabe, R, Greillier, L, Majem, M, Reguart, N, Monnet, I, Cousin, S, Garrido, P, Robinet, G, Campelo, RG, Madroszyk, A, Mazieres, J, Curcio, H, Wasag, B, Pretzenbacher, Y, Fournier, B, Dingemans, AMC, Dziadziuszko, R. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. ANNALS OF ONCOLOGY. 2023; 34(5)DOI:10.1016/j.annonc.2023.02.012. PMID:36863484. IF:56.700(Q1/1D).

01/05/2023 Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers

Lozano, R, Castro, E, -Campos, FL, Thorne, H, Ramirez-Backhaus, M, Aragon, IM, Cendon-Florez, Y, Gutierrez-Pecharroman, A, Salles, DC, Romero-Laorden, N, Lorente, D, Gonzalez-Peramato, P, Calatrava, A, Alonso, C, Anido, U, Arevalo-Lobera, S, Balmana, J, Chirivella, I, Juan-Fita, MJ, Llort, G, Cajal, TRY, Almagro, E, Alameda, D, Lopez-Casas, PP, Herrera, B, Mateo, J, Pritchard, CC, Antonarakis, ES, Lotan, TL, Rubio-Briones, J, Sandhu, S, Olmos, D. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. EUROPEAN JOURNAL OF CANCER. 2023; 185DOI:10.1016/j.ejca.2023.02.022. PMID:36972661. IF:7.600(Q1/2D).

30/03/2023 Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma A Nonrandomized Clinical Trial

Sanfilippo, R, Hindi, N, Jurado, JC, Blay, JY, Lopez-Pousa, A, Italiano, A, Alvarez, R, Gutierrez, A, Rincon-Perez, I, Sangalli, C, Aguiar, JLP, Romero, J, Morosi, C, Sunyach, MP, Fabbroni, C, Romagosa, C, Ranchere-Vince, D, Dei Tos, AP, Casali, PG, Martin-Broto, J, Gronchi, A. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma A Nonrandomized Clinical Trial. JAMA Oncology. 2023; 9(5)DOI:10.1001/jamaoncol.2023.0056. PMID:36995731. IF:22.300(Q1/1D).

08/03/2023 Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker

Martinez-Bosch, N, Vilarino, N, Alameda, F, Mojal, S, Arumi-Uria, M, Carrato, C, Aldecoa, I, Ribalta, T, Vidal, N, Bellosillo, B, Menendez, S, Del Barco, S, Gallego, O, Pineda, E, Lopez-Martos, R, Hernandez, A, Mesia, C, Esteve-Codina, A, de la Iglesia, N, Balana, C, Martinez-Garcia, M, Navarro, P. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. Cells. 2023; 12(6)DOI:10.3390/cells12060843. PMID:36980184. IF:5.100(Q2/4D).

27/02/2023 Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Chmielecki, J, Gray, JE, Cheng, Y, Ohe, Y, Imamura, F, Cho, BC, Lin, MC, Majem, M, Shah, R, Rukazenkov, Y, Todd, A, Markovets, A, Barrett, JC, Hartmaier, RJ, Ramalingam, SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-35961-y. PMID:36849494. IF:14.700(Q1/1D).

14/02/2023 Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312] (Cancer Treatment Reviews (2022) 102, (S0305737221001602), (10.1016/j.ctrv.2021.102312))

Blay J.Y., Hindi N., Bollard J., Aguiar S., Jr., Angel M., Araya B., Badilla R., Bernabeu D., Campos F., Caro-Sánchez C.H.S., Carvajal B., Carvajal Montoya A., Casavilca-Zambrano S., Castro-Oliden V., Chacón M., Clara M., Collini P., Correa Genoroso R., Costa F.D., Cuellar M., dei Tos A.P., Dominguez Malagon H.R., Donati D., Dufresne A., Eriksson M., Farias-Loza M., Fernandez P., Frezza A.M., Frisoni T., Garcia-Ortega D.Y., Gelderblom H., Gouin F., Gómez-Mateo M.C., Gronchi A., Haro J., Huanca L., Jimenez N., Karanian M., Kasper B., Lopes David B.B., Lopez-Pousa A., Lutter G., Martinez-Said H., Martinez-Tlahuel J., Mello C.A., Morales Pérez J.M., Moura David S., Nascimento A.G., Ortiz-Cruz E.J., Palmerini E., Patel S., Pfluger Y., Provenzano S., Righi A., Rodriguez A., Salas R., Santos T.T.G., Scotlandi K., Soule T., Stacchiotti S., Valverde C., Waisberg F., Zamora Estrada E., Martin-Broto J.. Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312] (Cancer Treatment Reviews (2022) 102, (S0305737221001602), (10.1016/j.ctrv.2021.102312)). CANCER TREATMENT REVIEWS. 2023; 115DOI:10.1016/j.ctrv.2023.102523. PMID:36796283. IF:9.600(Q1/1D).

01/02/2023 Direct materials for restoring caries lesions Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs

Pilcher, L, Pahlke, S, Urquhart, O, O'Brien, KK, Dhar, V, Fontana, M, Gonzalez-Cabezas, C, Keels, MA, Mascarenhas, AK, Nascimento, MM, Platt, JA, Sabino, GJ, Slayton, RL, Tinanoff, N, Young, DA, Zero, DT, Tampi, MP, Purnell, D, Salazar, J, Megremis, S, Bienek, D, Carrasco-Labra, A. Direct materials for restoring caries lesions Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION. 2023; 154(2)DOI:10.1016/j.adaj.2022.09.012. PMID:36610925. IF:3.100(Q1/2D).

02/01/2023 Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma

Trilla-Fuertes L., Gámez-Pozo A., Prado-Vázquez G., López-Vacas R., Zapater-Moros A., López-Camacho E., Lumbreras-Herrera M.I., Soriano V., Garicano F., Lecumberri M.J., de la Borbolla, MR, Majem M., Pérez-Ruiz E., González-Cao M., Oramas J., Magdaleno A., Fra J., Martín-Carnicero A., Corral M., Puértolas T., Ramos R., Vara, JAF, Espinosa E.. Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(1)DOI:10.3390/ijms24010801. PMID:36614248. IF:4.900(Q1/3D).

01/01/2023 Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial

Peters S., Letovanec I., Mauer M., Dafni U., Ejedepang D., Biernat W., Bubendorf L., Warth A., Pokharel S., Reinmuth N., Tarruella, MM, Casas-Martin J., Tsourti Z., Marti N., Kammler R., Danson S., O'Brien M., Stahel R.A.. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. LUNG CANCER. 2023; 175DOI:10.1016/j.lungcan.2022.12.004. PMID:36535121. IF:4.500(Q1/2D).